Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Jun 30, 2023
Revenue for the quarter was essentially flat compared to the immediately preceding quarter. Compared to the same quarter one year earlier, revenue increased.
Key takeaway
Quarter ended Jun 30, 2023 · FY2023 Q2
Revenue for the quarter was essentially flat compared to the immediately preceding quarter. Compared to the same quarter one year earlier, revenue increased.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.2B
Revenue reported for this quarter.
Quarter-over-quarter
-0.1%
Change from the immediately preceding quarter.
Year-over-year
+10.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$12.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2022 | $2.9B | -15.0% |
| Dec 31, 2022 | $3.4B | -31.0% |
| Mar 31, 2023 | $3.2B | +6.6% |
| Jun 30, 2023 | $3.2B | +10.5% |
Revenue performance
The reported revenue direction was stable sequentially, with a slight decline from the prior quarter. On a year-over-year basis, revenue showed growth.
Quarterly comparison
Revenue was nearly unchanged from the prior quarter, reflecting a marginal decrease. Compared with the same quarter a year ago, revenue was higher.
What to watch
The filing context does not provide specific causes for the revenue change; monitor future filings for underlying drivers.